SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle.
The new evacuated drainage bottle is the latest addition to Merit’s drainage portfolio. Offering a wide range of intervention products, solutions, and accessories, the comprehensive portfolio includes the Aspira System and ReSolve® line, thoracostomy, thoracentesis, and paracentesis trays and sets as well as bags and other support products.
The Aspira Drainage System is indicated for drainage of recurrent and symptomatic pleural effusions (fluid buildup outside the lungs) and malignant ascites (fluid buildup in the abdomen due to cancer). Individuals with these conditions commonly require frequent in-hospital drainage. Patient care may also include prolonged hospitalization or other treatments that can significantly reduce quality of life and diminish remaining survival.
When used with the Aspira System, the Aspira Bottle can provide the compassionate option to self-treat in the comfort of home, giving patients more time with loved ones. The bottle also offers convenience with its ease-of-use and advanced design that requires 23% less storage space than the leading drainage bottle on the market.1 To further optimize patient comfort, the Aspira Bottle allows users to control drainage speed, helping to minimize discomfort and pain associated with high vacuum pressure drainage.
Learn more about the Aspira Bottle.
“The Aspira Bottle is one more way Merit strives to improve patient care, which includes providing the option of at-home care,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “Bringing comfort to patients at every stage of life speaks to the heart of who Merit is—we care.”
ABOUT MERIT MEDICAL
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 700 individuals. Merit employs approximately 7,100 people worldwide.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | This email address is being protected from spambots. You need JavaScript enabled to view it.
1. Data on File.
Last Trade: | US$101.83 |
Daily Change: | 0.63 0.62 |
Daily Volume: | 289,523 |
Market Cap: | US$5.930B |
November 01, 2024 October 30, 2024 September 17, 2024 September 16, 2024 September 11, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB